Comments on: Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease

Comments on: Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease https://www.worldpharmatoday.com/news/merck-completes-enrollment-in-pivotal-phase-3-epoch-trial-investigating-the-efficacy-and-safety-of-verubecestat-in-patients-with-mild-to-moderate-alzheimers-disease/ Magazine for the C-level Pharma Executives Mon, 08 Feb 2016 07:05:19 +0000 hourly 1 https://wordpress.org/?v=6.9.4